• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Company launches product targeting dry eye, MGD

Article

ThermaMEDx has unveiled a self-heating, pre-moistened, disposable, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.

ThermaMEDx has unveiled a self-heating, pre-moistened, disposable, sterile cleaning eye-pad (EverTears) for use in treating the symptoms of dry eyes and meibomian gland dysfunction (MGD).

According to the company, the patented technology combines two proven treatments - - moist, precise heat and a sterile cloth cleaning pad into one easy to use, affordable product patients can use at-home.

Professor Michel Guillon, inventor of the patented technology, noted that the commercial launch of the product is the culmination of more than 30 years of research in Ocular Surface Disease.

“We are appreciative of all the support from doctors here at ThermaMEDx as well the enthusiastic response from eye care professionals throughout the US," Guillon, a scientist, innovator and optometrist practicing in London, England, said in a statement.

The eye-pad was unveiled in late March at the Texas Optometric Association meeting in Austin, with more than 92% of physicians surveyed indicating that they would recommend the product to their dry eye and MGD patients.

"We need more effective, affordable and convenient solutions for our Dry Eye patients to use at home, because compliance is a huge issue with home care,” Marguerite McDonald, MD, who performed the world's first laser vision correction procedure after years of research, said in a statement. “I have been impressed with how EverTears has brought the proper science to market in a product that many patients will actually enjoy using."

According to the company, the product will be available without a prescription from ophthalmologists nationwide beginning in June.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.